Loading…
Immunic, Inc. is projected to rise to $21.66 by 2027, a +47% move from its current price of $14.77. IMUX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $14.32 | $14.79 | $15.26 | +0.12% |
| Jul 14 | $14.15 | $14.80 | $15.49 | +0.23% |
| Jul 15 | $14.03 | $14.82 | $15.66 | +0.35% |
| Jul 16 | $13.92 | $14.84 | $15.81 | +0.46% |
| Jul 17 | $13.84 | $14.86 | $15.95 | +0.58% |
| Jul 18 | $13.76 | $14.87 | $16.08 | +0.69% |
| Jul 19 | $13.69 | $14.89 | $16.20 | +0.81% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.69 | $14.89 | $16.20 | +0.81% |
| Week 2 | $13.33 | $15.01 | $16.91 | +1.63% |
| Week 3 | $13.08 | $15.13 | $17.51 | +2.45% |
| Week 4 | $12.89 | $15.25 | $18.05 | +3.28% |
| Week 5 | $12.74 | $15.38 | $18.56 | +4.12% |
| Week 6 | $12.62 | $15.50 | $19.05 | +4.96% |
| Week 7 | $12.51 | $15.63 | $19.52 | +5.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immunic, Inc. (IMUX) is a biotechnology company focused on selective oral immunology therapies for chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical development for relapsing and progressive multiple sclerosis and in Phase 2 for moderate-to-severe ulcerative colitis.
The company also develops IMU-856, entering Phase 2, for restoration of the intestinal barrier function in gastrointestinal diseases, and IMU-381, in preclinical trial for gastrointestinal diseases.
Immunic was founded in 2016 and is headquartered in New York, New York.
Immunic, Inc. trades as IMUX in the Healthcare sector. It has a current price of $15.07 and a market capitalization of $205.28M, with a market rank of 3816.
The stock sits within the Healthcare category and currently shows a price around the mid-teens, providing a basis for its mid-term trajectory. The forecasted path shows a widening range over time, with a 2026 average near the current price and substantial upside in later years (2030 average $28.88 and 2050 average $259.57). The 2026 forecast also notes a min of $5.83 and a max of $24.86, indicating volatility in the near term.
Overall, the outlook is bullish for the longer horizon, with rising average prices and notable upside across multiple future years, culminating in very high potential by 2040 and beyond (e.g., 2040 average $143.68 and 2050 average $259.57).
A major floor 40.4% below — a decisive break under it would weaken the trend.
The nearest floor, 20.7% below — buyers have tended to step in here.
The nearest ceiling, 4.3% above — a clean break opens room to run.
A major ceiling 19.6% above — clearing it would confirm fresh momentum.
Key IMUX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMUX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.91 | Sell | $14.86 | Sell |
| MA 10 | $15.02 | Sell | $14.85 | Sell |
| MA 20 | $14.64 | Buy | $14.56 | Buy |
| MA 50 | $13.29 | Buy | $13.50 | Buy |
| MA 100 | $12.14 | Buy | $12.16 | Buy |
| MA 200 | $9.69 | Buy | $10.90 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.32 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 17.45 | Neutral |
| Williams %R (14) | -91.43 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -1.99 | Sell |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 8.57 | Buy |
| TRIX (15) | 0.61 | Buy |
| Awesome (5,34) | 0.72 | Buy |
| Ultimate (7,14,28) | 42.22 | Neutral |
| Momentum (10) | -0.30 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 14.81 | Sell |
| ADX (14) | 18.10 | Neutral |
| ATR (14) | 0.34 | Info |
The 30-day technical picture shows a bullish tilt for IMUX. The RSI(14) is 60, and the price has trended above the SMA50 of $12.11 and the SMA200 of $9.29, supporting a positive near-term bias.
Key support is at $11.55 and resistance at $15.13, suggesting a bounded upside near term. The 30-day price range is $11.42 to $19.89, highlighting recent volatility within a relatively wide channel.
Overall, the near-term setup aligns with a constructive posture, though volatility remains a factor given the sizable 30-day range and 80% annualized volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.83 | $14.77 | $23.00 | 0% | Neutral | |
| $16.98 | $21.66 | $29.38 | +47% | Bullish | |
| $19.96 | $26.31 | $37.23 | +78% | Bullish | |
| $21.90 | $29.68 | $43.39 | +101% | Bullish | |
| $21.61 | $30.01 | $45.10 | +103% | Bullish | |
| $26.23 | $37.25 | $57.33 | +152% | Bullish | |
| $31.49 | $45.67 | $71.81 | +209% | Bullish | |
| $36.89 | $54.55 | $87.46 | +269% | Bullish | |
| $43.54 | $65.61 | $107.06 | +344% | Bullish | |
| $45.96 | $70.52 | $116.98 | +377% | Bullish | |
| $74.35 | $123.87 | $220.06 | +739% | Bullish | |
| $126.82 | $244.26 | $479.18 | +15.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.83 | $14.77 | $18.21 | +0.00% |
| August 2026 | $13.65 | $16.18 | $19.74 | +9.52% |
| September 2026 | $13.73 | $16.41 | $20.28 | +1.42% |
| October 2026 | $13.60 | $16.36 | $20.45 | -0.26% |
| November 2026 | $14.18 | $17.17 | $21.65 | +4.91% |
| December 2026 | $14.86 | $18.09 | $23.00 | +5.38% |
Click any year to see its month-by-month IMUX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect IMUX to range from $5.83 to $23.00 through 2026. The $14.77 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The IMUX price prediction for 2027 points to an average of $21.66 (low $16.98, high $29.38) — a potential gain of +47% on today's $14.77. Buyers look set to stay in control over this stretch.
In 2028, IMUX is projected to trade between $19.96 and $37.23, averaging $26.31 — a potential gain of +78% from today's $14.77. That is up +21% on the projected 2027 average. Momentum favours further upside here.
Immunic, Inc.'s 2029 outlook centres on $29.68, within a $21.90 to $43.39 range. That is up +13% on the projected 2028 average. That marks a +101% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, IMUX could reach as high as $45.10, with a base case around $30.01 and support toward $21.61 — roughly +103% from $14.77. Momentum favours further upside here.
Expect IMUX to range from $26.23 to $57.33 through 2031. The $37.25 average target implies a +152% move from current prices. That is up +24% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The IMUX price prediction for 2032 points to an average of $45.67 (low $31.49, high $71.81) — a potential gain of +209% on today's $14.77. Momentum favours further upside here.
In 2033, IMUX is projected to trade between $36.89 and $87.46, averaging $54.55 — a potential gain of +269% from today's $14.77. That is up +19% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Immunic, Inc.'s 2034 outlook centres on $65.61, within a $43.54 to $107.06 range. That is up +20% on the projected 2033 average. That marks a +344% change versus current levels. Momentum favours further upside here.
By 2035, IMUX could reach as high as $116.98, with a base case around $70.52 and support toward $45.96 — roughly +377% from $14.77. Buyers look set to stay in control over this stretch.
Expect IMUX to range from $74.35 to $220.06 through 2040. The $123.87 average target implies a +739% move from current prices. That is up +76% on the projected 2035 average. Momentum favours further upside here.
The IMUX price prediction for 2050 points to an average of $244.26 (low $126.82, high $479.18) — a potential gain of +15.5x on today's $14.77. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMUX today (≈ 67.704807 IMUX) could be worth
$16,537.38
+$15,537.38 (+1554%) by 2050 · US Dollar
Based on the average projected IMUX price of $244.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMUXwould be worth at today's price.
$1,000 invested in IMUX on Jul 10, 2025 (≈ 119.331741 IMUX) would be worth
$1,762.53
+$762.53 (+76.3%) today · 1.76× · US Dollar
Based on a IMUX entry price of $8.38 vs. today's $14.77.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.8 | $997.97 | -0.2% |
| 1 month ago | $11.71 | $1,261.32 | +26.1% |
| 3 months ago | $11.7 | $1,262.39 | +26.2% |
| 6 months ago | $6.62 | $2,231.12 | +123.1% |
| 1 year ago | $8.38 | $1,762.53 | +76.3% |
| All time (5.0y) ago | $123.2 | $119.89 | -88.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMUX forecast.
Our base-case forecast reaches $30.00 around 2030.
Implied market cap at $30.00: $408.64M
The multi-year forecast shows continued upside with pronounced growth beyond 2026. In 2027 the average is $22.07 with a 46.5% ROI and bullish sentiment, followed by 2028 with an average of $27.07 and 79.6% ROI. In 2029 the average reaches $29.26 with a 94.2% ROI, and in 2030 the average is $28.88 with a 91.7% ROI and bullish sentiment.
Beyond 2030, the trajectory remains strong: 2031 average $39.68 (163.3% ROI), 2032 $49.75 (230.1%), 2033 $58.69 (289.4%), 2034 $73.16 (385.5%), and 2035 $74.13 (391.9%). The path continues to 2040 with an average of $143.68 and an 853.4% ROI, and reaches an average of $259.57 in 2050 with a 1622.4% ROI, all with bullish sentiment.
These figures illustrate substantial upside potential over the longer term, tempered by inherent uncertainty and the typical risks associated with translating clinical-stage developments into market-wide gains.
Tap a question to reveal the answer.
2030 forecast shows an average of $28.88 with a max of $46.68 and a min of $19.36, and a 91.7% ROI in the year, with bullish sentiment.
Forecasts show bullish sentiment across many years, with rising averages and ROI: 2027 avg $22.07 (46.5% ROI), 2028 avg $27.07 (79.6%), 2029 avg $29.26 (94.2%), and 2030 avg $28.88 (91.7%). These are estimates, not guarantees.
Yes. The forecast shows a max of $102.60 in 2033 and $130.67 in 2034, with higher later-year maxes such as $284.11 in 2040 and $576.76 in 2050, indicating potential to exceed $100 in the forecast horizon.
Current price is $15.07 and market cap is $205.28M.
For 2026, the min is $5.83, the avg is $15.07, the max is $24.86, with Neutral sentiment and 0% ROI.
Immunic, Inc. Community Discussion
0Share your Immunic, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.